Clinical Trials Sponsored by National Cancer Institute, Malaysia

Total 22085 results

National Cancer Institute (NCI)

Completed

Development and Validation of a Symptom Scale for Children With Chronic Graft-versus-Host Disease

Chronic Graft-Versus-Host-Disease

United States
National Cancer Institute (NCI)

Completed

Magnetic Resonance-Guided High-Dose Brachytherapy (Short-Range Radiation Therapy) for Prostate Cancer

Prostate Cancer

United States
National Cancer Institute (NCI)

Terminated

(11C)dLop as a Marker of P-Glycoprotein Function in Patients With Gliomas

Glioblastoma Multiforme | Oligoastrocytoma | Anaplastic Astrocytoma | Anaplastic Oligodendroglioma | Low Grade Glioma

United States
National Cancer Institute (NCI)

Completed

Ferumoxytol Enhanced MRI for the Detection of Lymph Node Involvement in Prostate Cancer

Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers

Neoplasms

United States
National Cancer Institute (NCI)

Completed

GW572016 to Treat Recurrent Malignant Brain Tumors

Glioma | Brain Tumor | Glioblastoma Multiforme | Gliosarcoma | GBM | GS

United States
National Cancer Institute (NCI)

Completed

A Pilot Study of EZN-2968, an Antisense Oligonucleotide Inhibitor of HIF-1alpha, in Adults With Advanced Solid Tumors With Liver Metastases

Neoplasms | Liver Metastases

United States
National Cancer Institute (NCI)

Terminated

Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal

Melanoma | Sarcoma | Pleural Malignancy | Epithelial Malignancies

United States
National Cancer Institute (NCI)

Terminated

Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation

Acute Lymphoblastic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Non-Hodgkins Lymphoma | Hodgkins Lymphoma

United States
National Cancer Institute (NCI)

Completed

Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer

Prostatic Neoplasms

United States
National Cancer Institute (NCI)

Completed

R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas

Neurofibroma, Plexiform | Neurofibromatosis Type I

United States, Germany
National Cancer Institute (NCI)

Completed

Self-Affirmation and Response to Health Risk Information

Alcohol Drinking | Emotions | Ego

United States
National Cancer Institute (NCI)

Completed

A Multi-Institutional Phase II Study of Cyclophosphamide, Paclitaxel, Cisplatin With G-CSF for Patients With Newly Diagnosed Advanced Stage Ovarian Cancer

Ovarian Neoplasm

United States
National Cancer Institute (NCI)

Terminated

Thyroid Abnormalities Associated With Exposure to Atmospheric Emissions of Radioactive Iodine

Thyroid Abnormalities

United States
National Cancer Institute (NCI)

Completed

Genetic Susceptibility to Factor VIII Inhibitors

Hemophilia

Sweden
National Cancer Institute (NCI)

Completed

Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma

Multiple Myeloma

United States
National Cancer Institute (NCI)

Terminated

p53 Vaccine for Ovarian Cancer

Ovarian Neoplasm

United States
National Cancer Institute (NCI)

Terminated

PU-H71 in Patients With Solid Tumors and Low-Grade Non-Hodgkin's Lymphoma That Have Not Responded to Standard Treatment

Lymphoma | Solid Tumors

United States
National Cancer Institute (NCI)

Completed

Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer

Renal Cell Carcinoma | Graft-Versus-Host Disease | Engraftment Syndrome

United States
National Cancer Institute (NCI)

Terminated

Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma

Melanoma | Skin Cancer

United States
National Cancer Institute (NCI)

Completed

T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers

Cervical Cancer | Anal Cancer | Vaginal Cancer | Oropharyngeal Cancer | Penile Cancer

United States
National Cancer Institute (NCI)

Completed

BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer

Metastatic Colorectal Cancer

United States
National Cancer Institute (NCI)

Completed

Positron Emission Tomography and Magnetic Resonance Imaging for Prostate Cancer

Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

T-Cell Project: Epidemiologic Component

Peripheral T-Cell Lymphoma

United States
National Cancer Institute (NCI)

Completed

A Pilot Study to Explore Serum and Imaging Biomarkers in Patients With Spinal Cord Compression

Cancer | Spine Metastasis

United States
National Cancer Institute (NCI)

Withdrawn

CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors

Sarcoma | Breast Cancer | Pancreatic Cancer | Ovarian Cancer | Colon Cancer

United States
National Cancer Institute (NCI)

Completed

Facilitating Web-based Patient Decision Support: Decision About Medication to Lower Breast Cancer Risk

Risk Reduction Behavior | High Risk for Breast Cancer

United States
National Cancer Institute (NCI)

Completed

A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma

Adenocarcinoma | Non-Small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including CNS Tumors and Lymphomas

Sarcoma | Lymphoma | Neuroblastoma | WilmsTumor

United States
National Cancer Institute (NCI)

Withdrawn

RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia

Sarcoma | Lymphoma | Brain Neoplasms | Osteosarcoma | Wilm's Tumor

United States
National Cancer Institute (NCI)

Completed

A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1a

Neoplasms

United States
National Cancer Institute (NCI)

Completed

Characterization of the Pharmacokinetics of Oral Selenium Compounds in Humans Before and Following Supplementation

Cancer

United States
National Cancer Institute (NCI)

Completed

Natural History Study of Moles and Suspicious Melanoma

Melanocytic Nevi | Acquired Melanocytic Nevi | Primary Cutaneous Melanoma

United States
National Cancer Institute (NCI)

Completed

Specimens From Normal Controls

Viral Infections

United States
National Cancer Institute (NCI)

Completed

Evaluation of the Association of Polymorphisms in the Innate Immune System With the Risk for Blastomycosis Dermatitidis Infection in Patients Not Infected With HIV and Complications Associated With Blastomycosis Dermatitidis Infection

Blastomycosis

United States
National Cancer Institute (NCI)

Completed

Late Effects of Treatment for Sarcomas in Children

Sarcoma

United States
National Cancer Institute (NCI)

Completed

Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas

Sarcoma

United States
National Cancer Institute (NCI)

Terminated

Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer

Fallopian Tube Neoplasms | Peritoneal Neoplasms | Epithelial Ovarian Cancer

United States
National Cancer Institute (NCI)

Completed

Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma

Cutaneous T Cell Lymphoma | Peripheral T Cell Lymphoma

United States, Australia
National Cancer Institute (NCI)

Completed

Phase II ABT-888 With Cyclophosphamide

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer | Triple-Negative Breast Cancer | Serous Carcinoma Cancer

United States, Canada
National Cancer Institute (NCI)

Terminated

O(6)-Benzylguanine and Temozolomide in Treating Patients With Glioblastoma Multiforme That Did Not Respond to Previous Temozolomide and Radiation Therapy

Brain and Central Nervous System Tumors

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Terminated

Ponatinib for Advanced Medullary Thyroid Cancer

Thyroid Neoplasms

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Terminated

Radiofrequency Ablation in Treating Patients With Unresectable Primary or Metastatic Liver Cancer

Unspecified Adult Solid Tumor, Protocol Specific | Metastatic Cancer | Liver Cancer

United States
National Cancer Institute (NCI)

Completed

TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma

Urothelial Carcinoma | Ureteral Neoplasms | Ureter Cancer | Cancer of the Ureter | Neoplasm, Ureteral

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Terminated

Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain

Sarcoma | Kidney Cancer | Ovarian Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Metastatic Cancer | Melanoma (Skin)

United States
National Cancer Institute (NCI)

Terminated

Imaging Studies of Kidney Cancer Using 18F-VM4-037

Kidney Neoplasms | Carcinoma, Renal Cell

United States
National Cancer Institute (NCI)

Completed

153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer

Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy

Thymic Carcinoma | Thymoma | Thymic Carcinoid | Thymic Neuroendocrine Tumors

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Colon Cancer That Has Not Responded to Vaccine Therapy

Lymphoma

United States
National Cancer Institute (NCI)

Completed

B-Lymphocyte Stimulator (BLyS) To Treat Selective IgA Deficiency

IgA Deficiency

United States

Clinical Trials Sponsored by National Cancer Institute, Malaysia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Switzerland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations